Benefits
Bacterial vaginosis recurrence prevention NEJM phase 2b RCT (Cohen 2020 PMID 32402161 PIVOTAL)
Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H et al. 2020 (NEJM 382:1906-1915, doi:10.1056/NEJMoa1915254, PMID 32402161) — PIVOTAL randomized double-blind placebo-controlled phase 2b trial. 228 women aged 18-45 with bacterial vaginosis who completed vaginal metronidazole gel. 2:1 randomization to Lactin-V (n=152) or placebo (n=76) for 11 WEEKS. RESULTS: 30% Lactin-V vs 45% placebo had RECURRENT vaginal dysbiosis at week 12 (risk ratio 0.66, p=0.01). L. crispatus CTV-05 detected in 79% Lactin-V at week 12 vs 2-6% placebo. NIH-funded. NEJM publication — gold-standard journal. Foundational pivotal evidence for first-of-class vaginal LBP.
Sustained colonization 24-week follow-up
Cohen 2020: L. crispatus CTV-05 detected in 79-84% Lactin-V participants during weeks 4, 8, 12. SUSTAINED detection in 48% at week 24 (13 weeks AFTER treatment cessation). Median concentration 1.7×10^6 to 6.2×10^6 CFU/mL during treatment + 5.6×10^6 CFU/mL at week 24. Important: sustained vaginal colonization beyond treatment period — distinguishing from typical short-acting interventions.
Genital immunology sustained effect (Armstrong 2022 Lancet Microbe)
Armstrong E, Hemmerling A, Miller S, Burke KE, Newmann SJ, Morris SR, Reno H, Huibner S, Kulikova M, Nagelkerke N, Coburn B, Cohen CR, Kaul R 2022 (Lancet Microbe, doi:10.1016/S2666-5247(22)00043-X) — substudy of NEJM trial. Vaginal levels of IL-1α + soluble E-cadherin at 24 weeks (13 weeks post-cessation). Mechanism: SUSTAINED EFFECT on genital immunology + epithelial barrier function. Important secondary endpoint supporting sustained mechanism beyond direct microbial colonization.
South Africa HIV acquisition risk phase 2 trial (PMC12173475)
PMC12173475 — phase 2 randomised placebo-controlled trial in South African women at HIGH RISK OF HIV ACQUISITION. Vaginal microbiota + genital tract inflammation outcomes. Important global generalizability evidence — distinct population from US NEJM trial. Mechanism context: vaginal Lactobacillus dominance associated with reduced HIV acquisition risk. Foundational HIV-prevention adjunct evidence.
Post-hoc antibiotic response predicts effectiveness (medRxiv 2023)
medRxiv 2023 (Cohen et al.) — post-hoc analysis of phase 2b LACTIN-V data. 88% of participants had achieved clinical BV cure at enrollment. RESPONSE TO ANTIBIOTIC TREATMENT PREDICTS EFFECTIVENESS of LACTIN-V — important biomarker stratification finding. Mechanism: antibiotic-induced niche clearance enables Lactin-V colonization. Important practical implication for clinical translation.
First-of-class vaginal LBP regulatory milestone
Lactin-V represents FIRST-OF-CLASS VAGINALLY-ADMINISTERED LIVE BIOTHERAPEUTIC PRODUCT in late-stage clinical development. NIH-funded research. Although NOT YET FDA APPROVED, NEJM publication + multi-trial evidence base position as leading vaginal probiotic candidate. Important for regulatory pathway in microbiome therapeutics.
L. crispatus dominance optimal vaginal health (mechanism context)
Lactobacillus species (especially L. crispatus) dominance is associated with optimal vaginal health, REDUCED HIV acquisition risk, REDUCED HPV persistence, REDUCED preterm birth. Low-Lactobacillus communities (<50% relative abundance) present in 25% of women globally + up to 50% sub-Saharan African women. Foundational epidemiological context for therapeutic application.
Mechanism of action
Vaginal niche colonization (vs placebo)
Lactin-V CTV-05 colonizes vaginal niche — detected in 79-84% participants at weeks 4-12 vs 2-6% placebo. Mechanism: direct administration + competitive establishment in dysbiotic vagina post-antibiotic. Foundational primary mechanism.
Lactic acid production + low pH maintenance
L. crispatus produces LACTIC ACID maintaining vaginal pH 3.5-4.5 — INHIBITS pathogenic Gardnerella, Atopobium, Mobiluncus, Prevotella growth. Foundation antimicrobial mechanism via pH-mediated competitive exclusion.
Hydrogen peroxide production
L. crispatus produces HYDROGEN PEROXIDE — broad-spectrum antimicrobial activity. Mechanism for direct pathogen suppression complementing pH-mediated effects.
Genital immunology + epithelial barrier modulation (Armstrong 2022)
Sustained effect on IL-1α + soluble E-cadherin at 24 weeks. Mechanism: vaginal mucosal immunity + epithelial barrier integrity modulation. Important sustained mechanism beyond direct microbial colonization.
Bacteriocin antimicrobial peptide production
L. crispatus produces bacteriocin-like substances active against vaginosis-associated bacteria. Mechanism: targeted antimicrobial activity beyond pH/H2O2 effects.
Biofilm disruption of pathogenic bacteria
L. crispatus disrupts biofilms formed by Gardnerella + other vaginosis pathogens. Mechanism: antibiofilm activity addressing recurrence root cause (biofilm persistence after antibiotics).
Antibiotic-Lactin-V sequential synergy
Sequential metronidazole → Lactin-V approach: antibiotic CLEARS dysbiotic flora → Lactin-V REPLACES with L. crispatus dominance. Mechanism: niche clearance + replacement therapy combined approach. medRxiv 2023 post-hoc shows antibiotic response predicts Lactin-V effectiveness.
Clinical trials
Randomized double-blind placebo-controlled phase 2b trial (Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H et al. 2020, NEJM 382:1906-1915, doi:10.1056/NEJMoa1915254, PMID 32402161). NIH-funded. 4 universities/hospitals USA.
228 women aged 18-45 years with bacterial vaginosis. ALL completed vaginal metronidazole gel as eligibility requirement. 2:1 randomization to Lactin-V (2×10^9 CFU per dose; n=152) or placebo (n=76) vaginally administered for 11 weeks. Follow-up through week 24.
PRIMARY OUTCOME: 30% Lactin-V vs 45% placebo had RECURRENT vaginal dysbiosis by week 12 (RR 0.66, p=0.01). L. crispatus CTV-05 detected in 79% Lactin-V at week 12 (84% at weeks 4, 8) vs 2-6% placebo. SUSTAINED detection in 48% at week 24. Foundational pivotal NEJM-published evidence. NOT YET FDA APPROVED — investigational status.
Substudy of NEJM phase 2b RCT (Armstrong E, Hemmerling A, Miller S, Burke KE, Newmann SJ, Morris SR, Reno H, Huibner S, Kulikova M, Nagelkerke N, Coburn B, Cohen CR, Kaul R 2022, Lancet Microbe, doi:10.1016/S2666-5247(22)00043-X). PMC9188188.
Subset of NEJM trial participants. Vaginal levels of IL-1α + soluble E-cadherin assessed at 24 weeks (13 weeks post-cessation). Multiplex ELISA + quantitative PCR for soluble immune factors + bacterial taxa.
SUSTAINED EFFECT on GENITAL IMMUNOLOGY + KEY VAGINAL BACTERIA at 24 weeks post-treatment cessation. Mechanism: long-term vaginal mucosal immunity + epithelial barrier modulation beyond direct microbial colonization. Important secondary endpoint extending NEJM primary findings.
Phase 2 randomised placebo-controlled trial (PMC12173475).
Women at HIGH RISK OF HIV ACQUISITION in South Africa. Lactin-V vs placebo. Outcomes: vaginal microbiota composition + genital tract inflammation + HIV-related immune markers.
Foundational HIV-prevention adjunct evidence in distinct global population (South African women — half of whom have low-Lactobacillus communities). Important global generalizability + HIV-prevention application beyond US BV recurrence. Mechanism: vaginal Lactobacillus dominance reduces HIV acquisition risk per epidemiological evidence.
About this ingredient
LACTIN-V™ is a VAGINALLY-ADMINISTERED LIVE BIOTHERAPEUTIC PRODUCT (LBP) commercialized by OSEL INC containing LACTOBACILLUS CRISPATUS CTV-05 strain. 2×10^9 CFU per vaginal applicator dose. Distinguishing application: VAGINAL ROUTE — distinct from oral probiotics. NOT FDA APPROVED — investigational status; available via clinical trials or off-label compounding. PIVOTAL CLINICAL EVIDENCE: COHEN 2020 NEJM PMID 32402161 (NEJM 382:1906-1915, doi:10.1056/NEJMoa1915254) PHASE 2b RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL — 228 women aged 18-45 with BV who completed vaginal metronidazole gel, 2:1 randomization to Lactin-V (n=152) or placebo (n=76) for 11 weeks. RESULTS: 30% Lactin-V vs 45% placebo had RECURRENT vaginal dysbiosis at week 12 (RR 0.66, p=0.01). L. crispatus CTV-05 detected in 79% (week 12) to 84% (weeks 4, 8) Lactin-V vs 2-6% placebo. SUSTAINED DETECTION in 48% at week 24 (13 weeks post-cessation). NIH-funded. ARMSTRONG 2022 (Lancet Microbe, PMC9188188) substudy — sustained effect on GENITAL IMMUNOLOGY (IL-1α + soluble E-cadherin) at 24 weeks. PMC12173475 South Africa phase 2 trial in women at HIGH RISK OF HIV ACQUISITION (different global population + HIV-prevention application). MEDRXIV 2023 post-hoc analysis: 88% participants achieved clinical BV cure at enrollment; ANTIBIOTIC RESPONSE PREDICTS LACTIN-V EFFECTIVENESS — important biomarker stratification.
MECHANISMS: VAGINAL NICHE COLONIZATION (79-84% detection vs 2-6% placebo); LACTIC ACID production maintaining vaginal pH 3.5-4.5 (inhibits Gardnerella + Atopobium + Mobiluncus + Prevotella); HYDROGEN PEROXIDE production (broad-spectrum antimicrobial); BACTERIOCIN antimicrobial peptide production; BIOFILM DISRUPTION of vaginosis pathogens; GENITAL IMMUNOLOGY + EPITHELIAL BARRIER MODULATION (sustained per Armstrong 2022); SEQUENTIAL ANTIBIOTIC-LACTIN-V SYNERGY (niche clearance + replacement therapy). EVIDENCE: 4/5 reflects: (1) COHEN 2020 NEJM PIVOTAL phase 2b RCT — gold-standard journal publication + statistical significance, (2) ARMSTRONG 2022 LANCET MICROBE substudy with sustained genital immunology evidence, (3) PMC12173475 South Africa phase 2 trial — global generalizability + HIV-prevention application, (4) WELL-CHARACTERIZED multi-mechanism action (colonization + lactic acid + H2O2 + bacteriocin + biofilm disruption + immunology), (5) NIH-FUNDED RESEARCH BASE — important regulatory + scientific credibility, (6) FIRST-OF-CLASS vaginal LBP in late-stage development, (7) SUSTAINED COLONIZATION + EFFECT (48% detection at 24 weeks post-treatment), (8) industry-sponsored (Osel Inc) — important context but NIH co-funding + multiple academic centers, (9) NOT YET FDA APPROVED — investigational status limits clinical accessibility, (10) higher-evidence than typical 'vaginal probiotic' due to NEJM publication + ECCO-equivalent regulatory pathway potential. SAFETY: Excellent — 24-week follow-up Cohen 2020 supportive. Best positioned as: (a) BACTERIAL VAGINOSIS RECURRENCE PREVENTION post-metronidazole (Cohen 2020 NEJM PIVOTAL evidence), (b) HIV-RISK REDUCTION ADJUNCT in high-risk populations (PMC12173475 South Africa evidence), (c) VAGINAL MICROBIOTA RESTORATION post-antibiotic, (d) GENITAL IMMUNOLOGY + EPITHELIAL BARRIER support (Armstrong 2022 sustained effect), (e) NOT YET FDA APPROVED — clinical trial enrollment or off-label compounding for access, (f) PREGNANCY: AVOID (trial exclusion criterion), (g) SEQUENTIAL DESIGN ESSENTIAL — metronidazole FIRST, then Lactin-V (NOT concurrent or substitution), (h) AVOID vaginal douches/spermicides during use, (i) emerging ADJUNCT for HPV persistence prevention, preterm birth prevention (mechanism context), (j) FIRST-OF-CLASS vaginal LBP — pioneering microbiome therapeutic. Honest framing: Lactin-V (L. crispatus CTV-05) represents the BEST-EVIDENCED VAGINAL PROBIOTIC in late-stage clinical development — Cohen 2020 NEJM PIVOTAL phase 2b RCT publication is gold-standard evidence rare among probiotics. The 30% vs 45% recurrence reduction (RR 0.66, p=0.01) is clinically meaningful. SUSTAINED COLONIZATION at 24 weeks post-treatment (48% detection 13 weeks after cessation) is genuinely distinguishing — most probiotics don't persist after stopping. Armstrong 2022 sustained genital immunology effects extend the mechanism beyond simple colonization. PMC12173475 South Africa HIV-risk evidence broadens application beyond US BV recurrence. SEQUENTIAL DESIGN ESSENTIAL — metronidazole first, then Lactin-V — practical clinical translation point. NOT YET FDA APPROVED is critical practical limitation — accessibility limited to clinical trials or off-label compounding. NIH-funded research + multi-center academic collaboration supports methodology rigor. Reasonable BV recurrence prevention adjunct based on rigorous NEJM-published evidence — particularly compelling for women with recurrent BV seeking evidence-based vaginal microbiome restoration. First-of-class vaginal LBP with regulatory pathway potential.